Title:
SALT AND CRYSTALLINE FORM OF PUROPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/111524
Kind Code:
A1
Abstract:
Salts and crystalline forms of the compound of chemical formula 1, that is, (R)-4-((2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[puro[3,4-d]pyrimidine-5,4'-piperidine]-3(2H,4H,7H)-yl)-1-phenylethyl)amino)butanoic acid according to the present invention are excellent in terms of general physicochemical properties, e.g., hygroscopicity, related substances, chemical stability, etc. and as such, can be utilized for pharmaceutical uses, such as the preparation of a pharmaceutical composition comprising same as an active ingredient.
More Like This:
| WO/2022/194096 | ESTROGEN RECEPTOR ANTAGONIST |
| WO/2021/204252 | TETRACYCLIC COMPOUND AS HEPATITIS B SURFACE ANTIGEN INHIBITOR |
| WO/2009/117036 | BIOACTIVE MOLECULES FROM CO-CULTIVATION OF MICROBES |
Inventors:
LEE MINHEE (KR)
KIM SEON-MI (KR)
KIM HUN-TAEK (KR)
KIM SEON-MI (KR)
KIM HUN-TAEK (KR)
Application Number:
PCT/KR2019/014164
Publication Date:
June 04, 2020
Filing Date:
October 25, 2019
Export Citation:
Assignee:
TIUMBIO CO LTD (KR)
International Classes:
C07D498/12; A61K31/519; A61K31/527; A61P5/24
Foreign References:
| KR20130102002A | 2013-09-16 | |||
| KR20180015264A | 2018-02-12 | |||
| KR20010090430A | 2001-10-18 | |||
| KR20110056242A | 2011-05-26 | |||
| KR20020045609A | 2002-06-19 | |||
| KR101495260B1 | 2015-02-26 | |||
| US9481684B2 | 2016-11-01 |
Other References:
See also references of EP 3889157A4
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: